The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer

Non-small cell lung cancer (NSCLC) is the most common cause of cancer related death in the world. Cisplatin and carboplatin are the most commonly used cytotoxic chemotherapeutic agents to treat the disease. These agents, usually combined with drugs such as gemcitabine or pemetrexed, induce objective...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Byrne, Kenneth J., Barr, Martin P., Gray, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756421/
https://www.ncbi.nlm.nih.gov/pubmed/24212667
http://dx.doi.org/10.3390/cancers3011426
_version_ 1782282093885128704
author O'Byrne, Kenneth J.
Barr, Martin P.
Gray, Steven G.
author_facet O'Byrne, Kenneth J.
Barr, Martin P.
Gray, Steven G.
author_sort O'Byrne, Kenneth J.
collection PubMed
description Non-small cell lung cancer (NSCLC) is the most common cause of cancer related death in the world. Cisplatin and carboplatin are the most commonly used cytotoxic chemotherapeutic agents to treat the disease. These agents, usually combined with drugs such as gemcitabine or pemetrexed, induce objective tumor responses in only 20–30% of patients. Aberrant epigenetic regulation of gene expression is a frequent event in NSCLC. In this article we review the emerging evidence that epigenetics and the cellular machinery involved with this type of regulation may be key elements in the development of cisplatin resistance in NSCLC.
format Online
Article
Text
id pubmed-3756421
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-37564212013-09-04 The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer O'Byrne, Kenneth J. Barr, Martin P. Gray, Steven G. Cancers (Basel) Review Non-small cell lung cancer (NSCLC) is the most common cause of cancer related death in the world. Cisplatin and carboplatin are the most commonly used cytotoxic chemotherapeutic agents to treat the disease. These agents, usually combined with drugs such as gemcitabine or pemetrexed, induce objective tumor responses in only 20–30% of patients. Aberrant epigenetic regulation of gene expression is a frequent event in NSCLC. In this article we review the emerging evidence that epigenetics and the cellular machinery involved with this type of regulation may be key elements in the development of cisplatin resistance in NSCLC. Molecular Diversity Preservation International (MDPI) 2011-03-17 /pmc/articles/PMC3756421/ /pubmed/24212667 http://dx.doi.org/10.3390/cancers3011426 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
O'Byrne, Kenneth J.
Barr, Martin P.
Gray, Steven G.
The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer
title The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer
title_full The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer
title_fullStr The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer
title_full_unstemmed The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer
title_short The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer
title_sort role of epigenetics in resistance to cisplatin chemotherapy in lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756421/
https://www.ncbi.nlm.nih.gov/pubmed/24212667
http://dx.doi.org/10.3390/cancers3011426
work_keys_str_mv AT obyrnekennethj theroleofepigeneticsinresistancetocisplatinchemotherapyinlungcancer
AT barrmartinp theroleofepigeneticsinresistancetocisplatinchemotherapyinlungcancer
AT graysteveng theroleofepigeneticsinresistancetocisplatinchemotherapyinlungcancer
AT obyrnekennethj roleofepigeneticsinresistancetocisplatinchemotherapyinlungcancer
AT barrmartinp roleofepigeneticsinresistancetocisplatinchemotherapyinlungcancer
AT graysteveng roleofepigeneticsinresistancetocisplatinchemotherapyinlungcancer

Ejemplares similares